Soleno Therapeutics Faces Class Action Lawsuit, Shareholder Alert Issued

Soleno Therapeutics Faces Class Action Lawsuit

A recent alert from The Gross Law Firm has garnered attention among shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). As concerns mount regarding the company's clinical trials, investors are being urged to join a class action lawsuit that could impact the future of the company and its investors.

Background

The Gross Law Firm's notice focuses on shareholders who acquired shares during a specific class period from March 26, 2025, to November 4, 2025. These investors are encouraged to reach out for potential lead plaintiff appointments, although it’s important to note that becoming a lead plaintiff is not a prerequisite for participating in any possible recovery.

Allegations Against Soleno Therapeutics

The class action centers around serious allegations against Soleno Therapeutics regarding its product, diazoxide choline extended-release tablets (DCCR). According to the complaint, the company and its executives may have issued materially false statements or failed to disclose crucial safety concerns linked to DCCR. The allegations include:

1. Downplaying Safety Issues: It is alleged that the company misrepresented significant safety concerns arising from the Phase 3 clinical trial program, particularly relating to excess fluid retention in participants.
2. Increased Safety Risks: As a result of the above, administering DCCR to treat hyperphagia in individuals with Prader-Willi Syndrome (PWS) is purported to present much greater safety risks than what was publicly communicated.
3. Commercial Viability Complications: The complaint further asserts that DCCR may face challenges in the market due to undisclosed risks, which include adverse events post-commercial launch, concerns regarding patient adherence, hesitance from prescribers, and potential regulatory hurdles.

These allegations raise significant concerns about the future commercialization of DCCR and the ensuing repercussions for shareholders.

Importance of Registering

The deadline for shareholders to register their claims is May 5, 2026. This step is crucial for invalidating potential losses incurred during the class period. By registering, investors will also be enrolled in a portfolio monitoring program that provides case updates, ensuring they are kept informed throughout the legal proceedings.

Those who have invested in Soleno Therapeutics must act swiftly to protect their interests. Delaying registration could mean missing out on potential recoveries. The Gross Law Firm highlights that there are no financial obligations to participate in this case, making it an accessible option for those affected.

Why Choose The Gross Law Firm?

Recognized nationally, The Gross Law Firm specializes in class action lawsuits and is dedicated to advocating for investor rights. Their mission is to hold companies accountable for deceitful practices that lead to financial loss. The law firm actively seeks to ensure companies comply with responsible business practices and engage positively with their investors.

Conclusion

As developments continue, shareholders of Soleno Therapeutics, Inc. are recommended to monitor communications from the Gross Law Firm closely. This legal action not only aims to address the potential mishaps associated with DCCR but reinforces the importance of corporate transparency and accountability in the healthcare industry. Investors hoping to learn more can contact The Gross Law Firm for assistance and guidance regarding the ongoing case.